MAVMET: Maraviroc ± Metformin for the Treatment of NAFLD in Virologically Suppressed Adults With HIV

October 27-30, 2021; London, United Kingdom
Maraviroc ± metformin, in addition to ART, was safe with acceptable tolerability but did not reduce liver fat percentage vs no adjunctive treatment.
Format: Microsoft PowerPoint (.ppt)
File Size: 164 KB
Released: November 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

Review the latest data on ART safety and tolerability in special populations in this slideset, from Clinical Care Options (CCO)

Jean Rene Anderson, MD Jill Blumenthal, MD, MAS Marta Boffito, MD, PhD, FRCP Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Joseph J. Eron, Jr., MD Julian Falutz, MD, FRCPC Eric K. Farmer, PharmD, BCPS, AAHIVP Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc William R. Short, MD, MPH, AAHIVS Darcy Wooten, MD Released: November 28, 2022

Clinical Care Options (CCO) downloadable slides from Drs Joseph Eron, Karine Lacombe, Chloe Orkin, and Babafemi Taiwo on HIV data from IDWeek and HIV Glasgow 2022

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 22, 2022

BICSTaR data on BIC/FTC/TAF effectiveness for PWH by demographics and baseline characteristics by Clinical Care Options (CCO) from HIV Glasgow 2022

Released: November 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings